UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2020

BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38659**	**26-4333375**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

54 Wilton Road, 2nd Floor **Westport, Connecticut**	**06880**
(Address of principal executive offices)	(Zip Code)

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

BioSig Technologies, Inc. (the "***Company***") intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences a slide presentation, which is attached hereto as Exhibit 99.1, regarding ViralClear Pharmaceuticals, Inc., a division of the Company. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	ViralClear Pharmaceuticals, Inc., Corporate Presentation, Spring, 2020 (furnished herewith pursuant to Item 7.01)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSIG TECHNOLOGIES, INC.

Date: March 30, 2020

By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman

Exhibit 99.1

Corporate Presentation

Spring 2020

PROPRIETARY & CONFIDENTIAL

Disclaimer

ViralClear

This presentation contains forward-looking statements including statements that address activities, events or developments that ViralClear Pharmaceuticals, Inc. ('ViralClear')expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, development and approvals of new products, market acceptance, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on ViralClear's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond ViralClear's control.

These risks and uncertainties include the timing of approval and development of products, rate and degree of market acceptance of products, ViralClear's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing ViralClear's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or ViralClear's ability to effectively react to other risks and uncertainties, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity and current worldwide economic conditions.

ViralClear does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, ViralClear undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Highlights

ViralClear

- Developed Vicromax – a powerful, broad spectrum, orally taken, **anti-viral agent to target COVID-19**
- Product has already undergone extensive animal testing and **human clinical experience** (134 treated patients) in other applications
- Proven to be **highly active against COVID-19** in cell culture
- **Softgel capsule** with two-year stability already exists
- Product **completed Phase I and three Phase II trials** in other indications
- **Proven management team** with significant pharmaceutical and anti-viral experience
- Robust **intellectual property** estate



Our Goal

ViralClear

To eliminate the
COVID-19
pandemic and offer
a preventive solution
to future viral threats

The Problem

ViralClear

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in 2019 in Wuhan, China, and has since spread globally, resulting in the 2019–20 coronavirus pandemic. While the majority of cases result in mild symptoms, some progress to severe pneumonia and multi-organ failure. The rate of deaths per number of diagnosed cases is on average 3.4%, ranging from 0.2% in those less than 20 to approximately 15% in those over 80 years old.

As of March 23, 2020, there have been 323,930 cases and 14,510 deaths confirmed worldwide. Global spread has been rapid, with 169 countries now having reported at least one case. The last time the world responded to a global emerging disease epidemic of the scale of the current COVID-19 pandemic with no access to vaccines was the 1918-19 H1N1 influenza pandemic, which killed at least 50 million people globally. Even with modern technology and healthcare, experts expect upwards of several million deaths globally as a result of COVID-19.

Sources: World Health Organization, Centers for Disease Control and Prevention, New York Times, Harvard Global Health Institute

ViralClear

An estimated

40% to 70%

of the world's population may be infected with

COVID-19

in the coming year*.

Sources: Mark Lipsitch, Harvard's Center for Communicable Disease Dynamics

Total Cases of COVID-19

ViralClear



Our Highly Effective Solution

ViralClear

- ViralClear has developed Vicromax - a small-molecule, oral anti-viral for the treatment of COVID-19 infections
- Laboratory tests indicate very good activity against COVID-19
- Acting alone or potentially in combination with other anti-virals or immune modulators
- Easy-to-swallow softgel capsule formulation
- Blister packaging with days of the week facilitates high degree of compliance

Key Advantages:

Phase 2 ready; tested in 134 patients in four separate studies

Given orally as a softgel or liquid

Small-molecule drug, which can rapidly scale to pandemic quantities

Extensive product development has already been completed

Our Product: Vicromax*

ViralClear

- A novel inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme responsible for stimulating the production of lymphocytes
- Has the potential to exert direct anti-viral activity, as well as immune response modifier
- An oral drug, formulated into softgels
- Available in blister packs for patient compliance and convenience

Reduces tissue culture COVID-19 production by over **90%**

* Commercial name is pending

Current Competition

ViralClear

- Anti-virals
- Anti-inflammatories
- Vaccines

Because of the immediate need for highly effective therapies, only anti-viral agents and anti-inflammatory medications that can enter the clinic in less than six months can address the current pandemic.

Our solution is one of the most advanced products in development with a short route and timeline to market.

Favilavir (favipiravir)
Anti-viral drug made in China by Zhejiang Hisun Pharmaceutical. The National Medical Products Administration of China approved Favilavir for clinical testing in patients for investigational COVID-19 treatment. Favilavir is currently approved for marketing in the treatment of influenza.

Remdesivir (GS-5734)
Ebola drug developed by Gilead Sciences that was found to be ineffective is now being tested in two Phase III randomized clinical trials in Asian countries.

Actemra
Developed by Roche to treat coronavirus-related complications.

Galidesivir
Developed by Biocryst Pharma as potential anti-viral for coronavirus treatment. Currently in advanced development stage under the Animal Rule to combat multiple potential viral threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses.

REGN3048-3051 and Kevzara
Developed by Regeneron and being tested as potential treatments for COVID-19.

Business Objectives

ViralClear

1. Develop highly effective products that eliminate COVID-19 and similar emerging viral diseases now and in the future
2. Initially and with the utmost urgency, introduce into COVID-19 clinical trials a softgel capsule formulation of Vicromax by the summer of 2020
3. Rapidly scale up commercial production to meet the current demand once significant clinical activity is observed and FDA approval is granted
4. Sustained revenue and profit growth to fund R&D and a pipeline of new formulations and products once the initial emergency need is met
5. Work with governments and public health organizations to stockpile the drug for future epidemics

Lifecycle Management Focused on COVID-19

ViralClear



Expand patient population

- Initial focus on symptomatic, hospitalized COVID-19 patients
  - Positive results should lead to initial approval
- Additional trials exploring other patients
  - Asymptomatic infected patients
  - Subjects exposed to infected patients at high risk of being infected

Conduct pre-clinical research on combination therapies

- Better refinement to understand the IC_{50} for the drug
- Test in tissue culture and in animals in combination with other anti-viral agents

Improve formulation

- Initially the legacy formulation that requires a cold chain will be used
- Since initial formulation was made, newer techniques have been developed
  - Elimination of cold chain
  - Robust liquid formulation

Short-Term Milestones Until Clinical Data

ViralClear

Depending on data, next steps TBD

Experienced Management Team

ViralClear

Nick Spring, BSc (Hons), DipM, MCIM – Chief Executive Officer

- Experienced executive with 35+ years of relevant experience in the life sciences industry
- Former executive at Merck; led the worldwide franchise for live viral human vaccines; led planning team for the launch of Gardasil®, HPV vaccine, in the US
- Former Founder and CEO of Topaz Pharmaceuticals Inc. (Acquired by Sanofi for $200+ million)
- Former CEO of Reliefband Technologies LLC and Partner, Life Sciences USA at Alten Calsoft

Steven King – Chief Operating Officer

- Seasoned pharmaceutical industry leader with 35+ years of relevant experience
- Worked on 500+ small molecule programs over his career, many from inception through to commercial launch
- Current President of 21159Pharma, which focuses on licensing and drug development
- Former Senior Vice President and Head of Business Development at Pii
- Previous experience working at Janssen (J&J company) and R P Scherer (Catalent)

Contact:

Nick Spring, CEO

Email:
nspring@biosigtech.com

Phone:
+1 (215) 962-0375